Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | PTPRC | P08575 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.39 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3810731 | 0.85 | KDM4E (0.44) | CYP2A6SIGMAR1KDM4EALDH1A1ALOX5 | |
| SCHEMBL202744 | 0.84 | CYP2A6 (0.66) | CYP2A6SIGMAR1PTPRCPTPN6PTPN11 | |
| SCHEMBL3813009 | 0.83 | SIGMAR1 (0.60) | CYP2A6SIGMAR1PTPRCPTPN6PTPN11 | |
| Hydrochloric Acid SCHEMBL31305343 | 0.82 | CYP2A6 (0.63) | CYP2A6SIGMAR1PTPRCPTPN6PTPN11 | |
| SCHEMBL13873189 | 0.81 | SIGMAR1 (0.57) | CYP2A6SIGMAR1PTPRCPTPN6PTPN11 | |
| SCHEMBL3789042 | 0.81 | CYP2A6 (0.61) | CYP2A6SIGMAR1PTPRCPTPN6PTPN11 | |
| SCHEMBL2091182 | 0.81 | CYP2A6 (0.61) | CYP2A6SIGMAR1PTPRCPTPN6PTPN11 | |
| SCHEMBL14756142 | 0.81 | CYP2A6 (0.72) | CYP2A6SIGMAR1KDM4EALDH1A1GAA | |
| SCHEMBL48070 | 0.81 | SIGMAR1 (0.64) | CYP2A6SIGMAR1PTPRCPTPN6PTPN11 | |
| Hydrochloric Acid SCHEMBL20564250 | 0.79 | CYP2A6 (0.70) | CYP2A6SIGMAR1KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101151257-B | Process for production of 1-(3-(2-(1-benzothiophen-5-yl)-ethoxy)propyl)azetidin-3-ol or salts thereof | TOYAMA CHEMICAL CO LTD | 2012-07-18 | — | — | CN | claimed |
| EP-2210884-B1 | Process for production of 1-(3-(2-(1-benzothiophen-5-yl)-ethoxy)propionic acid or salts thereof | TOYAMA CHEMICAL CO LTD (JP) | 2012-02-22 | — | — | EP | claimed |
| US-20110098484-A1 | PROCESS FOR PRODUCTION OF 1-(3-(2-(1-BENZOTHIOPHEN-5-YL)- ETHOXY)PROPYL)AZETIDIN-3-OL OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-04-28 | — | — | US | claimed |
| EP-2210884-A2 | Process for production of 1-(3-(2-(1-benzothiophen-5-yl)-ethoxy)propionic acid and 1-(3-(2-(1-benzothiophen-5-yl)-ethoxy)propyl)azetidin-3-ol as well as salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2010-07-28 | — | — | EP | claimed |
| US-20090069576-A1 | PROCESS FOR PRODUCTION OF 1-(3-(2-(1-BENZOTHIOPHEN-5-YL)-ETHOXY)PROPYL)AZETIDIN-3-OL OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD (JP) | 2009-03-12 | — | — | US | claimed |
| CN-101151257-A | Process for production of 1-(3-(2-(1-benzothiophen-5-yl)-ethoxy)propyl)azetidin-3-ol or salts thereof | TOYAMA CHEMICAL CO LTD (JP) | 2008-03-26 | — | — | CN | claimed |
| EP-1864978-A1 | PROCESS FOR PRODUCTION OF 1-(3-(2-(1-BENZOTHIOPHEN-5-YL)- ETHOXY)PROPYL)AZETIDIN-3-OL OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | claimed |
| WO-2023169481-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AS PAN-KRAS INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 思路迪生物医药(上海)有限公司 | 2023-09-14 | — | — | WO | disclosed |
| CN-114874201-B | Pan-KRAS inhibitor and preparation and application thereof | 思路迪生物医药(上海)有限公司 | 2023-01-20 | — | — | CN | disclosed |
| CN-114874201-A | Pan-KRAS inhibitor and preparation and application thereof | 思路迪生物医药(上海)有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-114075189-A | Five-membered heterocyclic acene ring compound and preparation method and medical application thereof | 南京柯菲平盛辉制药有限公司 | 2022-02-22 | — | — | CN | disclosed |
| EP-2348022-B1 | Process for production of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salts thereof | TOYAMA CHEMICAL CO LTD (JP) | 2013-01-09 | — | — | EP | disclosed |
| EP-2348022-B1 | Process for production of 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salts thereof | TOYAMA CHEMICAL CO LTD (JP) | 2013-01-09 | — | — | EP | disclosed |
| US-6797726-B1 | N-alkoxyalkyl-N,N-dialkylamine derivatives or salts thereof, and remedies for nerve degeneration diseases containing the same | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-09-28 | — | — | US | disclosed |
| EP-1437353-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2004-07-14 | — | — | EP | disclosed |
| EP-1186594-A1 | N-ALKOXYALKYL-N,N-DIALKYLAMINE DERIVATIVES OR SALTS THEREOF, AND REMEDIES FOR NERVE DEGENERATION DISEASES CONTAINING THE SAME | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-03-13 | — | — | EP | disclosed |
| EP-0129478-B1 | 2-SULFAMOYLBENZO (B) THIOPHENE DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ELEVATED INTRAOCULAR PRESSURE | MERCK & CO. INC. (US) | 1990-01-17 | — | — | EP | disclosed |
| US-4788192-A | TOPICALLY APPLYING; FOR GLAUCOMA | MERCK & CO., INC. (US) | 1988-11-29 | — | — | US | disclosed |
| US-4668697-A | Elevated intraocular pressure lowering benzo-[b]-thiophene-2-sulfonamide derivatives, compositions, and method of use therefor | MERCK & CO., INC. (US) | 1987-05-26 | — | — | US | disclosed |
| EP-0129478-A2 | 2-Sulfamoylbenzo (b) thiophene derivatives, their preparation and pharmaceutical composition for the treatment of elevated intraocular pressure | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069576-A1 | PROCESS FOR PRODUCTION OF 1-(3-(2-(1-BENZOTHIOPHEN-5-YL)-ETHOXY)PROPYL)AZETIDIN-3-OL OR SALTS THEREOF | PMP22, ACOX1, PAOX | CYP2A6 1393/4885SIGMAR1 1914/4885KDM4E 2675/4885 |
| US-20110098484-A1 | PROCESS FOR PRODUCTION OF 1-(3-(2-(1-BENZOTHIOPHEN-5-YL)- ETHOXY)PROPYL)AZETIDIN-3-OL OR SALTS THEREOF | PMP22, ACOX1, PAOX | CYP2A6 1393/4885SIGMAR1 1914/4885KDM4E 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.